The company's Confidence assays are designed to detect if a woman has a high-risk HPV subtype and, if so, determine her risk of developing cervical pre-cancer or cancer.
The agreement covers GynTect, which uses epigenetic biomarkers and methylation-specific PCR to determine if an HPV-positive patient is at risk for developing cervical cancer.
The French firm is assessing the Roche Cobas HPV test in preparation for a global Phase III clinical trial of its own therapeutic HPV vaccine.
The company and the hospital will conduct a clinical study into the detection and prevention of the disease.
Novacyt will validate its Novaprep liquid-based cytology platform with Abbott's RealTime High Risk human papillomavirus assay.
The Hologic-funded model predicted co-testing would lead to a lifetime savings of $39 per woman, with high cancer detection sensitivity and fewer false positive results.
IncellDx's investigational molecular assay used to quantify HPV E6/E7 mRNA in single cells has been optimized to run on Beckman Coulter's CytoFlex flow cytometry system.
The Netherlands is expected to be the first country to replace Pap cytology with HPV screening for first-line primary screening for cervical cancer.
HPV diversity could be caused by innate and adaptive immune responses and may have implications for understanding why some lesions become malignant.
A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.